Clinical Medicine Insights Endocrinology and Diabetes

Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study

By Nada Maher Mahmoud, Amal Hussein, Bashair M. Mussa, Salah Abusnana

Figure 1. Selection criteria for the studied population. — Figure 1. Selection criteria for the studied population.Selection criteria for the studied population.Mahmoud et al.

Cohort study of 199 peopleInterventions

18 months, declared no competing interests

The paper

Nada Maher Mahmoud, Amal Hussein, Bashair M. Mussa, Salah Abusnana

University of Sharjah

Clinical Medicine Insights Endocrinology and Diabetes, 24 Aug 2026

doi.org/10.1177/11795514261471399 PubMed 42643762

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19